Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TRIB 
Trinity Biotech plc (TRIB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TRIB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.54% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.59M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta 0.77 | 52 Weeks Range 0.48 - 3.39 | Updated Date 08/15/2025 |
52 Weeks Range 0.48 - 3.39 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -51.64% | Operating Margin (TTM) -42.73% |
Management Effectiveness
Return on Assets (TTM) -10.53% | Return on Equity (TTM) -1913.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 131184156 | Price to Sales(TTM) 0.58 |
Enterprise Value 131184156 | Price to Sales(TTM) 0.58 | ||
Enterprise Value to Revenue 2.13 | Enterprise Value to EBITDA -6.06 | Shares Outstanding 18632000 | Shares Floating 360842586 |
Shares Outstanding 18632000 | Shares Floating 360842586 | ||
Percent Insiders 12.01 | Percent Institutions 5.01 |
Upturn AI SWOT
Trinity Biotech plc
Company Overview
History and Background
Trinity Biotech plc was founded in 1992. It has grown through acquisitions and organic development to become a significant player in the clinical diagnostics market, focusing on point-of-care and laboratory-based diagnostics.
Core Business Areas
- Clinical Chemistry: Offers a wide range of clinical chemistry reagents and instruments for routine testing.
- Infectious Diseases: Develops and manufactures diagnostic tests for infectious diseases like HIV, malaria, and sexually transmitted infections.
- Autoimmunity: Provides tests for the diagnosis and monitoring of autoimmune diseases.
Leadership and Structure
The leadership team consists of experienced executives in diagnostics and healthcare. The company operates with a functional structure, with departments dedicated to R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- HIV Rapid Tests: Trinity Biotech offers rapid HIV tests for point-of-care settings. These tests compete with offerings from Abbott and Roche. Market share is estimated to be in the range of 5-10% globally, depending on the specific region and product. Revenue from this product is not publicly broken out by the company.
- Clinical Chemistry Reagents: Manufactures and sells a broad portfolio of clinical chemistry reagents. Competitors include Siemens Healthineers and Beckman Coulter. Market share varies significantly by region and specific reagent but can be estimated at around 1-3% globally overall.. Revenue from this product is not publicly broken out by the company.
Market Dynamics
Industry Overview
The clinical diagnostics industry is driven by aging populations, increasing prevalence of chronic diseases, and technological advancements. It's highly competitive, with both large multinational corporations and smaller specialized companies.
Positioning
Trinity Biotech holds a niche position, focusing on specific diagnostic areas and geographical markets. Its competitive advantages include its established brand and distribution network, particularly in emerging markets.
Total Addressable Market (TAM)
The global clinical diagnostics market is estimated to be in the hundreds of billions of USD. Trinity Biotech is positioned to address specific segments within this TAM, particularly in infectious disease and clinical chemistry diagnostics.
Upturn SWOT Analysis
Strengths
- Established brand reputation
- Strong distribution network in key markets
- Focus on specific diagnostic areas
- Cost-effective manufacturing capabilities
Weaknesses
- Relatively small size compared to major competitors
- Limited R&D resources
- Dependence on specific geographic markets
- High debt levels
Opportunities
- Expansion into new geographic markets
- Development of innovative diagnostic solutions
- Strategic partnerships and acquisitions
- Increasing demand for point-of-care diagnostics
Threats
- Intense competition from larger players
- Regulatory changes and reimbursement pressures
- Economic downturns in key markets
- Technological disruptions
Competitors and Market Share
Key Competitors
- Roche Holding Ltd (RHHBY)
- Abbott Laboratories (ABT)
- Siemens Healthineers (SIEGY)
- Danaher Corporation (DHR)
- QuidelOrtho Corporation (QDEL)
Competitive Landscape
Trinity Biotech faces significant competition from larger, more diversified players. Its success depends on focusing on niche markets, developing innovative products, and maintaining a cost-effective manufacturing base.
Major Acquisitions
Immunodiagnostic Systems Holdings PLC (IDS)
- Year: 2022
- Acquisition Price (USD millions): 82
- Strategic Rationale: IDS acquisition enables TRIB to penetrate automated specialty immunoassay segment.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by acquisitions and organic revenue growth in key diagnostic segments.
Future Projections: Future growth projections are not readily available without access to analyst reports and company guidance. These projections depend on market conditions and company execution.
Recent Initiatives: Recent initiatives would be things like new product launches, strategic partnerships, and cost-cutting measures, which are information unavailable in real time.
Summary
Trinity Biotech operates in a competitive diagnostics market with a focus on niche segments. The company has an established brand and distribution network but faces challenges from larger competitors and debt. Successful growth hinges on innovation, strategic partnerships, and effective execution in key markets. Recent acquisitions should help boost revenues but risks from regulation and key competitor growth need to be watched closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Market research reports
- Financial news sources
- Analyst reports
- SEC filings
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Trinity Biotech plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1995-08-18 | President, CEO, Company Secretary & Director Mr. John Gillard | ||
Sector Healthcare | Industry Medical Devices | Full time employees 401 | Website https://www.trinitybiotech.com |
Full time employees 401 | Website https://www.trinitybiotech.com | ||
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.